Rapid ART initiation at CrescentCare Health Clinic within 72 hrs of diagnosis and prior to obtaining laboratory results was effective and well tolerated in adults and young persons (18-24 yrs) with HIV.
Higher rates of virologic suppression at delivery and fewer adverse birth outcomes in treatment-naive women initiating DTG-based ART vs EFV/FTC/TDF during pregnancy.
Phase III data demonstrate that long-acting cabotegravir + rilpivirine injections every 2 months is noninferior to monthly injections at Week 48 in virologically suppressed patients with no prior virologic failure.
Long-term pooled analysis of Studies 1489 and 1490 demonstrated comparable efficacy and safety, including renal and bone outcomes, in older and younger patients initiating BIC/FTC/TAF vs DTG-based 3-drug regimens.
Switch to monthly injections of long-acting cabotegravir + rilpivirine after 20-week induction with oral 3-drug ART in treatment-naive patients noninferior to continued oral 3-drug ART for the maintenance of virologic suppression at Week 96 and demonstrates higher patient-reported satisfaction.
Detailed analysis of confirmed virologic withdrawals shows low risk of treatment-emergent resistance in treatment-naive patients treated with DTG/3TC for initial ART.
Changes in weight, body fat, BMD, and fasting lipid parameters were comparable among varying doses of islatravir + DOR vs DOR/3TC/TDF at Week 48 in ART-naive patients.
Increases in adipose tissue and predicted 10-year risk of diabetes significantly higher with use of DTG + FTC/TAF compared with DTG + FTC/TDF or EFV/FTC/TDF in treatment-naive patients initiating ART in South Africa.
Post hoc analysis found that patients initiating EFV-based ART who were categorized by CYP2B6 genotyping as slow metabolizers had less weight gain compared with extensive metabolizers and those initiating DTG-based ART.
Longer-term follow-up demonstrates continued noninferior efficacy and more favorable bone and renal safety profile of FTC/TAF vs FTC/TDF for HIV prevention in MSM and transgender women.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.